BioCentury
ARTICLE | Clinical News

BIT225: Additional Phase IIa data

January 9, 2012 8:00 AM UTC

Additional data from a double-blind, Thai Phase IIa trial in 24 treatment-naïve patients with HCV genotype 1 infection showed that twice-daily oral BIT225 for 28 days plus standard of care (SOC; peginterferon alfa-2b and ribavirin) led to a complete early virologic response (cEVR) rate, defined as undetectable HCV RNA levels (<50 IU/mL) at week 12, of 87% vs. 63% for placebo plus SOC. BIT225 was generally well tolerated with nausea reported as the most common adverse event. Patients received SOC plus twice-daily 200 or 400 mg oral BIT225 or placebo for 28 days followed by SOC alone for 44 weeks. Data were presented at the HEP DART meeting in Koloa. ...